Knight Therapeutics Inc. (TSX: GUD) announced that it has repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin, a strategic move to expand its pan-American pharmaceutical business.
The repayment was funded through strong cash flow generated by the company’s operations in Canada and Latin America, according to the announcement. This development underscores Knight’s ability to generate sufficient cash from its core business to reduce debt, which could strengthen investor confidence in the company’s financial health and operational efficiency.
Importantly, the revolving credit facility remains in place, continuing to provide borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature available subject to certain conditions. This means Knight retains significant financial flexibility to pursue its ongoing growth strategy across its pan-American pharmaceutical operations without the immediate burden of outstanding debt from the Paladin acquisition.
The news is significant for the pharmaceutical industry and investors monitoring Canadian and Latin American markets. By repaying the debt ahead of schedule or as planned, Knight Therapeutics demonstrates disciplined capital management. The company’s ability to use operational cash flow—rather than additional financing or asset sales—to retire the debt suggests robust performance in its core markets.
Knight Therapeutics, headquartered in Montreal, Canada, focuses on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma, and Laboratorio LKM. The company’s shares trade on the TSX under the symbol GUD. For more information about the company, visit www.knighttx.com.
The repayment also removes any near-term refinancing risk and reduces interest expenses, potentially improving profitability. For the broader industry, it highlights that mid-cap pharmaceutical companies can successfully integrate acquisitions while maintaining a healthy balance sheet.
To view the full press release, visit https://ibn.fm/8eluB.
